Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Like c-Fos, HBZ (
HTLV-I
bZIP factor) is able to interact with
c-Jun
but differs considerably from c-Fos in its ability to activate AP-1-responsive genes since HBZ rather inhibits transcriptional activity of
c-Jun
. To better understand the molecular mechanisms involved in this down-regulation of
c-Jun
activity, a large number of HBZ/c-Fos chimeras was constructed and analyzed for their ability to interact with
c-Jun
, to bind to the AP-1 motif and to stimulate expression of a reporter gene containing the collagenase promoter. By this approach, we demonstrate that the DNA-binding domain of HBZ is responsible for its inhibitory effect on the trans-activation potential of
c-Jun
. However, unexpectedly, we found that exchange of a cluster of six charged amino acids immediately adjacent to the DNA contact region altered significantly transcriptional activity of chimeras. This particular subdomain could be involved in efficient presentation of the AP-1 complex to the transcriptional machinery. To confirm this role, specific residues present in the cluster of HBZ were substituted for corresponding amino acids in c-Fos. Unlike the JunD-activating potential of wild-type HBZ, this mutant was no longer able to stimulate JunD activity, confirming the key role of this particular cluster in regulation of Jun transcriptional potency.
...
PMID:A modified version of a Fos-associated cluster in HBZ affects Jun transcriptional potency. 1671 81
HTLV-I
bZIP factor (HBZ) contains a C-terminal zipper domain involved in its interaction with
c-Jun
. This interaction leads to a reduction of
c-Jun
DNA-binding activity and prevents the protein from activating transcription of AP-1-dependent promoters. However, it remained unclear whether the negative effect of HBZ-SP1 was due to its weak DNA-binding activity or to its capacity to target cellular factors to transcriptionally-inactive nuclear bodies. To answer this question, we produced a mutant in which specific residues present in the modulatory and DNA-binding domain of HBZ-SP1 were substituted for the corresponding c-Fos amino acids to improve the DNA-binding activity of the
c-Jun
/HBZ-SP1 heterodimer. The stability of the mutant, its interaction with
c-Jun
, DNA-binding activity of the resulting heterodimer, and its effect on the
c-Jun
activity were tested. In conclusion, we demonstrate that the repression of
c-Jun
activity in vivo is mainly due to the HBZ-SP1-mediated sequestration of
c-Jun
to the HBZ-NBs.
...
PMID:Propensity for HBZ-SP1 isoform of HTLV-I to inhibit c-Jun activity correlates with sequestration of c-Jun into nuclear bodies rather than inhibition of its DNA-binding activity. 1959 8